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Abstract: 
This study examined factors accounting for functional performance limitations in 100 long-term survivors of 
allogeneic hematopoietic stem cell transplantation with chronic graft-versus-host disease (cGVHD). Functional 
performance, measured by the SF-36 physical component summary score, was substantially lower (mean = 36.8 
± 10.7) than the US population norm of 50 (P<0.001). The most severe decrements were in physical function 
(mean = 38.8 ± 10.9) and physical role function (mean = 37.88 ± 11.88); 68% of respondents exceeded the five-
point threshold of minimum clinically important difference below the norm on these subscales. Controlling for 
age and gender, six variables explained 56% of the variance in functional performance: time since cGVHD 
diagnosis, cGVHD severity, intensity of immunosuppression, comorbidity, functional capacity (distance walked 
in 2 min, grip strength, and range of motion), and cGVHD symptom bother (F=11.26; P<0.001).Significant 
independent predictors of impaired performance were intensive systemic immunosuppression, reduced capacity 
for ambulation, and greater cGVHD symptom bother (P<0.05). Symptom bother had a direct effect on 
functional performance, as well as an indirect effect partially mediated by functional capacity (Sobel test, P = 
0.004). Results suggest two possible mechanisms underlying impaired functional performance in survivors with 
cGVHD and underscore the importance of testing interventions to enhance functional capacity and reduce 
symptom bother. Bone Marrow Transplantation (2010) 45, 762–769; doi:10.1038/bmt.2009.238; published 
online 28 September 2009 
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Article: 
Introduction 
Chronic graft-versus-host disease (cGVHD) affects 30–80% of individuals who survive for > 100 days after 
allogeneic hematopoietic stem cell transplant (HSCT) and causes significant morbidity and mortality.
1–3
 This 
late complication of HSCT has heterogeneous, multisystem clinical manifestations including mucocutaneous, 
ocular, gastrointestinal, hepatic, musculoskeletal, and immunologic impairments. Chronic GVHD is also 
associated with a graft-versus-tumor effect that may confer a survival benefit .
4,5
 Although our understanding of 
the basic biology of cGVHD is improving and therapeutic advances are being made, the clinical impact of 
cGVHD has not been well-characterized. 
 
Studies of quality of life in survivors of allogeneic HSCT suggest that cGVHD is associated with impairments 
in functional status,
6–11
 with specific effects on physical function; domestic and vocational role function; and 
marital, family, and social interaction.
1,12–14
 Relative to transplant survivors without cGVHD, those with 
cGVHD have lower physical, sexual, and social functioning
14
 and show impaired physical and psychosocial 
recovery 1 year after transplant 
12,13,15
 and beyond.
16–18
 No prior studies have explicitly characterized functional 
performance or its predictors in a sample of HSCT survivors experiencing cGVHD. Existing studies of HSCT 
survivors have focused on health-related quality of life, a broad, multidimensional outcome of which physical 
function is just one element. This literature suggests that age, gender 
,6,19–21
 intensity of immunosuppression,
6
 
cGVHD severity, 
12,16,22
 time since the cGVHD diagnosis,1 
0,23
 comorbidity,
1,17,22
 and symptom distress
7,10,14,17
 
are factors that may be relevant to functional performance in allogeneic HSCT survivors with cGVHD. The 
purpose of this study was to determine the factors that account for variability in functional performance in long-
term allogeneic HSCT survivors with cGVHD. 
 
Materials and methods 
Design, participants, setting 
Data for this cross-sectional analysis were prospectively gathered from the first 100 sequentially recruited adults 
participating in a natural history study of cGVHD (clinicaltrials.gov; #NCT00331968). Data were collected 
from October 2004 until December 2007. Eligible study participants were referred from oncologists and 
allogeneic transplant centers from around the United States and were over age 18; were at least 100 days post 
transplant; had the diagnosis of cGVHD established through clinical signs and/or tissue biopsy of one or more 
organ systems;
24
 and were literate in English or Spanish. 
 
Permission for the study was granted by the Institutional Review Board of the Intramural Research Program of 
the Center for Cancer Research, National Cancer Institute. Each subject participated in a 4-day, comprehensive, 
multidisciplinary evaluation. Self-report measures were administered via personal interview immediately after 
study enrollment. Measures of functional capacity, and demographic and clinical data were collected through 
clinical and diagnostic evaluations. On the basis of a series of multidisciplinary examinations and diagnostic 
testing, the severity of cGVHD involvement was scored using standardized criteria.
24 
 
Measures 
Functional performance. Functional performance was evaluated using the physical component summary 
(PCS) score of the SF-36, version 2, a widely used and extensively validated 
25,26
 multidimensional generic 
measure of functional health and well-being. The 36 items of the SF-36 evaluate eight factors: physical 
functioning, physical role functioning, bodily pain, general health, vitality, social functioning, emotional-role 
functioning, and mental health 
.25,27–29
 The PCS score and the mental component summary score 
30
 are derived 
by using a standard algorithm to aggregate scores across the eight subscales. Lower scores on the PCS indicate 
limitations in physical functioning and role participation, a high degree of bodily pain, and an unfavorable 
perception of general health .
30
 The use of norm-based scoring
30
 facilitates the interpretation of SF-36 scores 
such that any score below 50 is below the US population mean, and each point represents one-tenth of a 
standard deviation. 
 
Functional capacity. Measures of functional capacity included the distance walked in 2 min, dominant hand 
grip strength (Jamar hydraulic hand dynamometer; Bissell Healthcare Corporation, Jackson, MI, USA), and 
upper and lower body range of motion (ROM). All measures were obtained in a single session by one of two 
rehabilitation professionals, and in accordance with written testing procedures 
.31,32
 The 2-min walk distance 
was chosen over the more commonly used 6-min walk because of a concern that study participants would have 
insufficient endurance to complete 6-min walk test procedures. Studies support the construct validity and 
responsiveness of the 2-min walk distance as a measure of functional capacity in other chronically ill 
populations 
.33–35
 Five of the 100 participants in this study were not ambulatory and were therefore excluded 
from 2-min walk distance procedures. 
 
Active assisted ROM measurements in the supine position were taken using a standard goniometer. Partici-
pants’ mean bilateral ROM measurements were converted to the percentage of normal ROM, using the 
American Academy of Orthopaedic Surgeons ’
32
 definition of normal ROM for each joint. Measurements that 
exceeded the maximum value were assigned a score of 100. Joints with fixed contractures were assigned a score 
of 0. An aggregate score 
36
 was calculated representing the patient’s average degree of impairment in upper and 
lower body ROM. 
Chronic GVHD symptom bother. The degree to which respondents have been bothered in the past month by 
each of 30 symptoms was assessed using the Lee cGVHD symptom scale.
37
 A summary score was created by 
taking the mean of all items and linearly transforming that value to a0–100 scale.
37
 
 
Comorbidity. Comorbidity was measured using the total score on the Functional Comorbidity Index .
38
 The 
Functional Comorbidity Index has favorable psychometric properties when functional status is the outcome of 
interest .
39
 In this study, the Functional Comorbidity Index was completed by a clinician, based on a 
comprehensive evaluation. 
 
Clinician-rated cGVHD severity. Clinician-rated cGVHD severity and the number of sites involved with 
cGVHD were evaluated using the NIH consensus criteria.
24
 The extent of involvement of each of eight organ 
systems typically affected by cGVHD (skin, mouth, eyes, lungs, GI tract, liver, joints/fascia, and in women, the 
genitalia) was rated, and a summative score reflecting cGVHD severity was calculated. This scoring was 
completed by a consistent team of organ system subspecialists (for example oral medicine, dermatology, 
gynecology) and other transplant experts, all of whom have extensive experience with cGVHD. 
 
Intensity of immunosuppression. The intensity of current systemic immunosuppression was classified as 
follows: a low intensity regimen was defined as treatment with prednisone alone at a dose of < 0. 5 mg/kg/day. 
Moderately intense regimens included single agent prednisone at a dose ≥ 0.5 mg/kg/day, and/or any other 
single agent or modality. Regimens comprised of two or more agents or modalities (± prednisone ≥ 0.5 
mg/kg/day), were categorized as highly intensive systemic immunosuppression. When scoring the intensity of 
systemic immunosuppression, the use of topical agents was not captured. 
 
Other variables. Disease risk categories were classified using the definitions validated by Parimon et al.
40
 
Low-risk diseases included chronic myelogenous leukemia in chronic phase, refractory anemia, and aplastic 
anemia. Intermediate-risk diseases included chronic myelogenous leukemia in accelerated phase or in chronic 
phase after blastic phase, acute leukemia or lymphoma in remission, refractory anemia with excess blasts, 
chronic lymphocytic leukemia, and paroxysmal nocturnal hemoglobinuria. High-risk diseases included chronic 
myelogenous leukemia in blastic phase, juvenile chronic myelogenous leukemia, acute leukemia or lymphoma 
in relapse, refractory anemia with excess blasts in transformation, myeloma, solid tumor, and nonhematologic 
diseases. 
 
Statistical analysis 
Multiple regression analysis was performed to determine the contributions the following five blocks of variables 
make in explaining the variability in functional performance: demographic factors (age and gender); clinical- 
and treatment-related factors (cGVHD severity, time since cGVHD diagnosis, intensity of immunosuppression); 
comorbidity; functional capacity; and cGVHD symptom bother. All blocks were simultaneously entered into the 
model. 
 
Post hoc hierarchical multiple regression analyses were conducted to explore whether mediation fully or 
partially explained the relationships among the significant predictor variables and the outcome of functional 
performance .41 SPSS version 15.0 was used for all analyses. The α level of significance was set at 0.05. 
 
Results 
Demographic and clinical characteristics 
Sample characteristics are presented in Tables 1 and 2. Participants (N=100) were primarily Caucasian (90%), 
married (67%), and a mean age of 46 years (± 11.8). Males (52%) and females (48%) were approximately 
equally represented. Forty-one percent of the sample worked full time, were full-time students, or were 
homemakers. Participants were a mean of 42.6 months (± 37.5) post transplant (median, 31 months; range, 4–
201 months). Chronic GVHD had been diagnosed a median of 25 months before their evaluation at study 
enrollment, and at the time of enrollment, all participants had evidence of cGVHD organ involvement as 
defined by the NIH consensus guidelines for diagnosis and staging.
24
 Participants had a mean of 2.6 ( ± 1.5) 
comorbidities or late effects of transplantation in addition to cGVHD. The most prevalent comorbidities were 
osteoporosis (53%), depression (43%), peripheral neuropathy (38%), upper gastrointestinal disease (21%), 
degenerative disc disease (20%), and obesity (body mass index > 30) (17%). 
             
The profiles of functional capacity and performance are presented in Table 3 and Figure 1. As seen in Figure 1, 
the mean PCS and seven of eight SF-36 subscale scores were significantly lower than the US general population 
normative value of 50 (P<0.001). Moreover, based on a minimum clinically important difference of three points 
for the PCS and five points for the subscales,
30,42
 78% of the sample reported clinically important functional 
performance limitations, with a substantial portion showing meaningful impairment in physical function (68%), 
physical role function (68%), social function (72%), vitality (54%), and role-emotional function (44%). 
 
Linear regression model of functional performance 
As shown in Table 4, the linear combination of demographic and clinical variables accounted for over half 
(56%) of the variation in functional performance. All of the blocks of variables, the demographic intensity of 
immunosuppression, the distance walked in 2 min, and cGVHD symptom bother were significant independent 
predictors of functional performance, and explained 3, 21, and 19% of the variance, respectively, while 
controlling for the remaining variables. 
 
Mediation model of functional performance 
To determine whether symptom bother leads directly to decrements in functional performance, or whether 
functional capacity is an intermediary in this relationship, the mediation model depicted in Figure 2 was 
estimated using hierarchical multiple regression. Significant results for all three regression equations are 
interpreted as evidence of mediation.
41,43
 Post hoc probing to determine whether the mediation path was 
significantly greater than zero was conducted using Sobel’s equation.
41,44
 In all analyses, intensity of 
immunosuppression was used as a covariate. 
 
Controlling for intensity of immunosuppression, cGVHD symptom bother was significantly associated with 
functional performance, explaining 38% (adjusted R
2
 = 0.38) of the variation in functional performance. 
Chronic GVHD symptom bother was also significantly associated with functional capacity, when the effect of 
intensity of immunosuppression was controlled. Finally, when controlling for both symptom bother and 
intensity of immunosuppression, functional capacity was associated with functional performance; and 
simultaneously, the association of functional performance and symptom bother, controlling for intensity of 
immunosuppression, remained significant. The indirect path between symptom bother and functional 
performance through functional capacity was significant (Sobel test, P=0.004). Thus, functional capacity 
partially mediated the relationship between cGVHD symptom bother and functional performance, with 26% of 
the variation in functional performance explained by symptom bother accounted for by the mediation pathway 
through functional capacity. 
         
 
 
 
Discussion 
This study explored functional performance limitations in patients with cGVHD by testing two types of models 
designed to examine the direct and indirect effects of selected clinical and demographic factors on this outcome 
in a sample of 100 long-term survivors with cGVHD after allogeneic HSCT. 
 
Consistent with earlier research, 
16,17,22
 participants in this study showed substantial impairment in both func-
tional capacity and performance, showing a level of functional performance that was significantly inferior to US 
population norms. The normed-means on the SF-36 for physical function, physical role function, bodily pain, 
and general health were also 6–15 points lower than the normed-means reported in a small sample of very long-
term (median of 17.5 years post transplant) allogeneic HSCT survivors, only 50% of whom were noted to have 
cGVHD .
45
 Our results suggest that individuals with moderate-to-severe cGVHD requiring treatment with 
moderate-to-high levels of immunosuppression experience significant functional limitations. These limitations 
climbing stairs, walking distances, and performing moderately vigorous activities, as well as reduced endurance 
for household tasks and other work, and unfavorable perceptions of general health. 
 
It was surprising to find that neither comorbidity nor objectively scored cGVHD severity was a significant 
predictor of functional performance limitations in our sample of allogeneic HSCT survivors. As a prior report 
observed a small, positive association between comorbidity and functional status in patients with cancer,
46
 it is 
possible that comorbidity and cGVHD severity may have a function in limiting functional performance in 
transplant survivors with cGVHD, and this should be explored in a larger sample. 
 
Earlier studies indicate that the presence of immunosuppressive therapy may not have an adverse effect on 
health-related quality of life .
6
 However, our study measured the intensity of systemic immunosuppressive 
therapy, not just its presence/absence, and showed a significant relationship with functional performance. From 
a clinical perspective, more intensive immunosuppression regimens, particularly regimens containing high 
doses of corticosteroids, may contribute to a side-effect profile,
47,48
 including tremor and muscle weakness, that 
results in impaired physical function, though this hypothesis has not yet been empirically tested in HSCT 
survivors receiving immunosuppression for cGVHD. 
 
Other investigators have also observed an association between the occurrence of multiple symptoms and 
adverse functional performance 
.49–51
 However, our study results are novel in showing that in long-term 
allogeneic HSCT survivors with cGVHD, the adverse effects of symptoms on functional performance are both 
direct, and indirect mediated through decrements in functional capacity. 
 
Several limitations must be considered in the interpretation of our study results. The sample size was relatively 
small, and the cross-sectional design did not permit a conclusion that the observed relationships are solely the 
result of cGVHD. Individuals seen at our referral center may also have more severe, intractable, or 
heterogeneous manifestations of cGVHD, and the observations and associations may not hold if the 
relationships were examined in another setting or in individuals with less severe or less intractable cGVHD 
manifestations. Caution should be used in generalizing these results to patients with mild or subclinical 
cGVHD. 
 
With these caveats in mind, this study fills an important gap in knowledge by examining the effects of 
symptoms, functional capacity, and clinical- and treatment-related factors on functional performance in a 
sample comprised exclusively of allogeneic HSCT survivors with cGVHD. These results may be helpful in 
planning interventions for this patient population, a population shown in prior research to be at particular risk 
for morbidity and mortality. For example, the findings underscore the importance of close follow-up of patients 
with cGVHD to ensure thorough evaluation of functional capacity and symptom bother, and to provide 
rehabilitative interventions targeted to improve functional capacity. Interventions to evaluate and effectively 
manage cGVHD symptoms and reduce symptom bother are also essential and may contribute to better 
functional performance directly, as well as indirectly by elevating functional capacity. Study results also suggest 
that patients receiving intensive immunosuppression are at particular risk for impairments in functional 
performance and represent a group who might benefit from early intervention. 
 
These study results also support the utility of three instruments recommended by the National Institutes of 
Health for use as dimensions of therapeutic response evaluation in cGVHD:
52
 the SF-36, the distance walked in 
2 min, and the Lee chronic GVHD symptom bother scale. Measures of functional performance and functional 
capacity offer complementary information about functional status in this patient population, and the inclusion of 
differing dimensions of function and contrasting methodologic approaches to measuring functional outcomes in 
clinical trials of new therapies appears warranted. 
 
Results suggest several directions for future research. Specifically, longitudinal studies are needed to determine 
whether early declines in functional capacity produce subsequent performance limitations, and to test whether 
interventions specifically designed to elevate functional capacity and ameliorate symptom bother lead to 
improvements in functional performance. Research is indicated to develop and refine screening measures that 
can be used to identify cGVHD patients with clinically significant symptom bother, declines in functional 
capacity, and deterioration in performance of activities in daily life. 
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